Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?

Company Overview - Rhythm Pharmaceuticals, Inc. (RYTM) shares increased by 5.5% to close at $57.52, supported by high trading volume compared to normal sessions, following a 2.7% decline over the past four weeks [1] Financial Performance - The company reported preliminary net revenues of approximately$ 42 million for Q4 2024 and around $130 million for the full year 2024 from worldwide sales of Imcivree (setmelanotide), which may have contributed to the recent share price increase [2] - The upcoming quarterly report is expected to show a loss of$ 0.72 per share, reflecting a year-over-year change of -2.9%, while revenues are anticipated to be $36.23 million, marking a 49.5% increase from the same quarter last year [3] Earnings Estimates - The consensus EPS estimate for Rhythm Pharmaceuticals has been revised 1% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting favorable market sentiment [4] Industry Context - Rhythm Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Ultragenyx (RARE), saw a 3.2% increase to$ 41.28, despite a -8.8% return over the past month [4] - Ultragenyx's consensus EPS estimate has changed by +1.5% to -$1.28, representing a +15.8% change from the previous year, and it currently holds a Zacks Rank of 3 (Hold) [5]